Dai X, et al. - The intention of the researchers was to comparatively evaluate the adverse drug events (ADEs) related to a low (10 mg) vs a high (25 mg) dose of empagliflozin as (1) monotherapy, (2) as an add-on to other oral hypoglycemic agents (OHAs), and (3) as an add-on specifically to metformin, in subjects treated for type 2 diabetes mellitus (T2DM). No prominent variation was found in the incidence of ADEs among T2DM patients receiving 10 vs 25 mg empagliflozin as monotherapy or as add-on to metformin or other anti-diabetic drugs during a shorter or longer follow-up period. Nevertheless, findings displayed that genital and urinary tract infections (UTIs) were more common in female patients with T2DM regardless of empagliflozin dosage.